In May 2025, significant developments emerged in the biotechnology sector. ASXAN BIOTECH GROUP(hereinafter referred to as "ASXAN") and Yunnan Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax Biotech") officially joined forces by jointly investing in the establishment of Aisenze Biotechnology (Kunming) Co., Ltd. The core mission of this new company is to build an advanced photobiosynthesis technology and industrialization platform. This move marks a substantial step for both parties in the field of precision photobiosynthesis for medical and health natural products, aiming to jointly inaugurate a new era of synthetic biology industrialization based on Yunnan's unique plateau resource endowment.
It is reported that the newly established Aisenze Biotechnology (Kunming) Co., Ltd. will focus on the precision photobiosynthesis of medical and health natural products. Currently, the platform's industrialization construction and market preparation are progressing in an orderly manner. The company will strive to leverage its comprehensive advantages in industrialization in the future, fully accelerating project progress to achieve scaled production at an early date and inject robust new momentum into the sustainable and long-term development of both partners.
This strategic collaboration represents a keen move by the partners to actively seize the major developmental opportunities presented by the nation's inclusion of biomanufacturing in its strategic emerging industries and future industries. Walvax Biotech stated that it would fully utilize Yunnan Province's unique advantages, including its rich biodiversity resources, green electricity, and abundant biomass resources. Combined with its own mature technology platforms and R&D-manufacturing capability system, Walvax aims to achieve deep strategic positioning in this cutting-edge field of biomanufacturing. Its product pipeline planning extends beyond the natural products initially focused on in this collaboration, broadly encompassing areas such as nutrients, active natural product ingredients, and functional proteins, demonstrating vast development prospects.
As a key partner, ASXAN is the China-based entity of the multinational biotech group ASXAN Group. Although ASXAN was registered and established in January 2025, its technological accumulation is profound, with the group's origins traceable back to 2009. Its core competitiveness lies in its independently invented ATPS (Aqueous Two-Phase System) microalgae photobio-cell synthesis technology, which has successfully transitioned from the laboratory stage to achieve a "remarkable transformation" to industrial scale. The ASXAN Group's portfolio includes several star innovative nutrient products, such as the premium astaxanthin product AstaMAZ®, FucoSLIM® fucoxanthin, and AlgaeOmega® algal oil.These products have not only achieved compliance with regulatory requirements of the U.S. FDA and the European Food Safety Authority (EFSA), but also continue to drive the evolution and innovation of the industry landscape through revolutionary synthetic biology technologies, fulfilling the mission to “revitalize every cell with technology.”
The strategic alliance between ASXAN and Walvax Biotech represents not only an efficient complementarity of the two companies' technological, resource, and market strengths but also a proactive response to Yunnan Province's strategy for developing a bio-economy. The establishment of the Aisenze platform is expected to become a significant engine for promoting the industrial application of plateau-specific synthetic biology technologies, contributing "Yunnan Wisdom" and "Yunnan Solutions" to the development of China's biomanufacturing industry.